The Effects of Antiglaucoma Ophthalmic Solutions on the Cornea Revealed by a Corneal Electrical Resistance Device.

Purpose: We sought to evaluate the effect of antiglaucoma ophthalmic solutions on the cornea with a corneal resistance device (CRD), and to compare the results with those by fluorescein staining.

Methods

In 6 rabbit groups (n = 7 each), right eyes were administered latanoprost ophthalmic solution containing 0.02% benzalkonium chloride (BAK); dorzolamide/timolol (1%/0.5%) containing 0.005% BAK; dorzolamide/timolol without BAK; dorzolamide/timolol+latanoprost with 0.02% BAK; 0.005% BAK; or 0.02% BAK to the conjunctival sac 3 × at 15-min intervals. Left (control) eyes were administered saline. Baseline and post-treatment corneal resistance (CR) were measured. The CR ratio = CR before versus after treatment. We evaluated superficial punctate keratitis by fluorescein staining using area and density (AD) grades.

Results

In the dorzolamide/timolol-without BAK group, there were no significant difference in the CR ratio between the control and treatment eyes at any time point. In the 0.005%-BAK group at 30 min and the other 4 groups at all time points, the CR ratio differed significantly between the control and treatment eyes (P < 0.05). AD grades were 0 in all control eyes and the dorzolamide/timolol-without BAK and 0.005% BAK treatment eyes.

Conclusions

Nonpreservative ophthalmic solutions (and those with low BAK concentrations) do not significantly affect corneal electrical resistance. Eye drop ingredients other than BAK may be involved in altering corneal electrical resistance. CRDs may detect corneal epithelium changes not revealed by fluorescein staining.